ACVR1B & TGFBR1 Knockout HEK293 Cell Line

The choice depends on whether you are studying combined activin (ALK4) and TGF-β (ALK5) type I receptor signaling or distinguishing their contributions to SMAD2/3 activation. The Double Knockout line is uniquely valuable for asking whether ALK4/ALK5 are required for SMAD2/3 signaling — ACVR1B/ALK4 (activin type I receptor) and TGFBR1/ALK5 (TGF-β type I receptor) are the two principal SMAD2/3-activating type I receptors; ALK4 transduces activin signals and ALK5 transduces TGF-β signals, but they share the SMAD2/3 effector branch. Combined ALK4/ALK5 knockout eliminates most SMAD2/3-activating signaling. Single-isoform rescue (ALK4 alone or ALK5 alone) enables receptor-specific dissection of activin versus TGF-β signaling. For SMAD2/3 signaling research, the EDITGENE ACVR1B & TGFBR1 Double Knockout in HEK293 is the gold-standard genetic tool for distinguishing activin from TGF-β signaling — single knockouts retain residual SMAD2/3 activation from the other receptor. Single-isoform rescue is the gold-standard experimental design. The double knockout is a critical specificity tool for ⭐ galunisertib (LY2157299, ALK5 inhibitor in cancer clinical development), vactosertib (TEW-7197), SB-431542 (research ALK4/5/7 inhibitor), and emerging TGF-β/activin pathway-targeted therapeutics in cancer and fibrosis.

Primary applications: • SMAD2/3 signaling elimination: activin- and TGF-β-induced phospho-SMAD2/3 analysis — substantially abolished in the double KO. • Single-isoform rescue: ⭐ re-introduction of ALK4 alone or ALK5 alone enables receptor-specific dissection of activin vs TGF-β signaling — gold-standard experimental design. • ALK5 inhibitor specificity: critical genetic control for ⭐ galunisertib (LY2157299), vactosertib (TEW-7197), SB-431542 in cancer/fibrosis drug development. • TGF-β/activin pathway dissection: systematic analysis of the two principal SMAD2/3-activating receptors. EDITGENE recommends this double knockout as the gold-standard genetic tool for distinguishing activin from TGF-β signaling and for TGF-β/activin pathway drug development.

Yes, and rescue experiments are uniquely powerful in this double knockout: • Single-isoform rescue: ⭐ re-introduction of ALK4 (ACVR1B) alone or ALK5 (TGFBR1) alone enables receptor-specific dissection of activin vs TGF-β SMAD2/3 signaling — gold-standard experimental design. • Construct design: use codon-modified ACVR1B or TGFBR1 sequences with small intracellular C-terminal tags (FLAG, HA) — preserve extracellular, GS, and kinase domains. • Kinase-dead rescue: K234R (ALK4) or K232R (ALK5) ATP-binding lysine mutations abolish catalytic activity. • Constitutively active rescue: T206D (ALK4) or T204D (ALK5) GS domain mutations generate constitutively active receptors. • Functional readout: rescue should restore activin (ALK4) or TGF-β (ALK5)-induced phospho-SMAD2/3. HEK293 transduces efficiently with lentivirus and supports systematic isoform-specific rescue experiments.